Germany

CureVac

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

GSK invests in mRNA vaccines through deal with CureVac

Lead Product(s): CV7301

Therapeutic Area: Infections and Infectious Diseases Product Name: CV7301

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: GlaxoSmithKline

Deal Size: $1,179.0 million Upfront Cash: $141.4 million

Deal Type: Collaboration July 20, 2020

Details:

The Collaboration Agreement will Facilitate Research, Development, Manufacturing and Commercialisation of up to Five mRNA-Based Vaccines and Monoclonal Antibodies (mAbs) Targeting Infectious Disease Pathogens.

Mundipharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Laboratory Studies Confirm BETADINE(R) Antiseptic Products' Effectiveness Against COVID-19 Virus

Lead Product(s): Povidone-Iodine

Therapeutic Area: Infections and Infectious Diseases Product Name: Betadine

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 09, 2020

Details:

Testing has demonstrated BETADINE's® strong in-vitro virucidal activity, killing 99.99% of the SARS-CoV-2 virus in 30 seconds. The products subjected to testing were: BETADINE® antiseptic products, Skin Cleanser, Gargle and Mouthwash and Throat Spray.

IgNova

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

IgNova Files Patent Application on Antibody Against COVID-19

Lead Product(s): IgY antibody

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 23, 2020

Details:

The patented IgY binds the spike protein of SARS-CoV-2, neutralizing the virus when it enters the mouth or nose and, therefore, inhibiting the infection process. IgNova's technology offers a safe, economical, and unlimited source of polyclonal antibodies to control SARS-CoV-2.

CureVac

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

CureVac´s Optimized mRNA Platform Provides Positive Pre-Clinical Results at Low Dose for Coronavirus Vaccine Candidate

Lead Product(s): COVID-19 mRNA vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 14, 2020

Details:

The data showed a fast induction of a balanced immune response with high levels of virus neutralizing titers (VNTs) and T-cell responses. VNTs are a major criterion supporting that the vaccine candidate has the potential to induce a strong immunologic response.

BioNTech SE

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

BioNTech and Fosun to Develop mRNA Vaccine for COVID-19

Lead Product(s): BNT162

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Fosun Pharma

Deal Size: $180.0 million Upfront Cash: $135.0 million

Deal Type: Collaboration March 16, 2020

Details:

The collaboration aims to accelerate development of BioNTech’s potential first-in-class COVID-19 mRNA vaccine program, BNT162.

BioNTech SE

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

BioNTech reports rapid progress on COVID-19 vaccine program to address global public health threat

Lead Product(s): BNT162

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 16, 2020

Details:

BioNTech intends to initiate clinical testing for BNT162 in late April 2020, as part of a global clinical development program in Germany, the United States and China for COVID-19.

CureVac

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

CureVac and CEPI extend their Cooperation to Develop a Vaccine against Coronavirus nCoV-2019

Lead Product(s): nCoV-2019 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: CEPI

Deal Size: $34.0 million Upfront Cash: $8.3 million

Deal Type: Collaboration January 31, 2020

Details:

The aim of the cooperation is to safely advance vaccine candidates into clinical testing as quickly as possible for Protection against Corona virus.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

CureVac

GSK invests in mRNA vaccines through deal with CureVac

Mundipharma

Laboratory Studies Confirm BETADINE(R) Antiseptic Products' Effectiveness Against COVID-19 Virus

IgNova

IgNova Files Patent Application on Antibody Against COVID-19

CureVac

CureVac´s Optimized mRNA Platform Provides Positive Pre-Clinical Results at Low Dose for Coronavirus Vaccine Candidate

BioNTech SE

BioNTech and Fosun to Develop mRNA Vaccine for COVID-19

BioNTech SE

BioNTech reports rapid progress on COVID-19 vaccine program to address global public health threat

CureVac

CureVac and CEPI extend their Cooperation to Develop a Vaccine against Coronavirus nCoV-2019